{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:52:19Z","timestamp":1785520339621,"version":"3.56.0"},"reference-count":100,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T00:00:00Z","timestamp":1455580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institute Pasteur Italy","award":["year 2012"],"award-info":[{"award-number":["year 2012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains. This review exemplifies the various studies made to investigate the effect of chirality on the antiretroviral activity of top HIV-1 NNRTI compounds, such as nevirapine (NVP), efavirenz (EFV), alkynyl- and alkenylquinazolinone DuPont compounds (DPC), diarylpyrimidine (DAPY), dihydroalkyloxybenzyloxopyrimidine (DABO), phenethylthiazolylthiourea (PETT), indolylarylsulfone (IAS), arylphosphoindole (API) and trifluoromethylated indole (TFMI) The chiral separation, the enantiosynthesis, along with the biological properties of these HIV-1 NNRTIs, are discussed.<\/jats:p>","DOI":"10.3390\/molecules21020221","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T10:39:15Z","timestamp":1455619155000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors"],"prefix":"10.3390","volume":"21","author":[{"given":"Valeria","family":"Famiglini","sequence":"first","affiliation":[{"name":"Institute Pasteur Italy\u2014Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Universit\u00e0 di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-0178","authenticated-orcid":false,"given":"Romano","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Institute Pasteur Italy\u2014Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Universit\u00e0 di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,2,16]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization HIV\/AIDS, Fact Sheet n. 360, Updated November 2015. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1570162X13666150827093449","article-title":"Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses","volume":"14","author":"Veillette","year":"2016","journal-title":"Curr. HIV Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Landais, E., Huang, X., Havenar-Daughton, C., Murrell, B., Price, M.A., Wickramasinghe, L., Ramos, A., Bian, C.B., Simek, M., and Allen, S. (2016). Broadly neutralizing antibody responses in a large longitudinal sub-saharan HIV primary infection cohort. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005369"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grand","year":"2010","journal-title":"New Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Esposito, F., Corona, A., and Tramontano, E. (2012). HIV-1 reverse transcriptase still remains a new drug target: Structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions. Mol. Biol. Int., 2012.","DOI":"10.1155\/2012\/586401"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments","volume":"98","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_8","unstructured":"U.S. FDA (2015). Antiretroviral Drugs Used in the Treatment of HIV Infection, U.S. FDA."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/v3040347","article-title":"Clinical management of HIV drug resistance","volume":"3","author":"Cortez","year":"2011","journal-title":"Viruses"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","article-title":"Understanding and managing the adverse effects of antiretroviral therapy","volume":"85","author":"Hawkins","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","volume":"10","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","article-title":"The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS)","volume":"67","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bcp.2013.07.012","article-title":"Dancing with chemical formulae of antivirals: A personal account","volume":"86","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bcp.2013.09.010","article-title":"Dancing with chemical formulae of antivirals: A panoramic view","volume":"86","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_15","unstructured":"AIDSinfo Side Effects of HIV Medicines, Available online: https:\/\/aidsinfo.nih.gov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go?","volume":"53","author":"Mehellou","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2015.09.015","article-title":"Meeting report: 28th International conference on antiviral research in Rome, Italy","volume":"123","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhan, P., Pannecouque, C., de Clercq, E., and Liu, X. (2015). Anti-HIV drug discovery and development: Current innovations and future trends. J. Med. Chem.","DOI":"10.1021\/acs.jmedchem.5b00497"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1389200023337982","article-title":"Combinations against combinations: Associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations","volume":"3","author":"Maga","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1073\/pnas.88.23.10895","article-title":"Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5 \u00c5 resolution","volume":"88","author":"Clarck","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/jmbi.1994.1665","article-title":"Locations of anti-AIDS drug binding sites and resistant mutations in the three dimensional structure of HIV-1 reverse trancriptase","volume":"243","author":"Tantillo","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1126\/science.1377403","article-title":"Crystal structure at 3.5 \u00c5 resolution of HIV-1 reverse transcriptase complexed with an inhibitor","volume":"256","author":"Kohlstaedt","year":"1992","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsb0495-293","article-title":"High resolution structures of HIV-1 RT from four RT-inhibitor complexes","volume":"2","author":"Ren","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1006\/jmbi.1996.0698","article-title":"Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant","volume":"264","author":"Das","year":"1996","journal-title":"J. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1126\/science.1163108","article-title":"Slide into action: Dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates","volume":"322","author":"Liu","year":"2008","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nsb0495-303","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors","volume":"2","author":"Esnouf","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"ref_28","unstructured":"AIDSinfo Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Available online: http:\/\/aidsinfo.nih.gov\/guidelines."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0163-7827(02)00046-2","article-title":"Effects of HIV protease inhibitor therapy on lipid metabolism","volume":"42","author":"Hui","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.2055","article-title":"Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen","volume":"65","author":"Delaugerre","year":"2001","journal-title":"J. Virol. Med."},{"key":"ref_31","unstructured":"Brown, C. (1990). Chirality in Drug Design and Synthesis, Academic Press."},{"key":"ref_32","unstructured":"Federsel, H.J. (2007). Compregensive Medicinal Chemistry II, Elsevier."},{"key":"ref_33","unstructured":"Soudijn, W. (1983). Stereochemistry and Biological Activity of Drugs, Blackwell Scientific Publications."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/cen-v070n024.p005","article-title":"FDA issues flexible policy on chiral drugs","volume":"70","author":"Borman","year":"1992","journal-title":"Chem. Eng. News"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1021\/cen-v070n039.p046","article-title":"In wake of new FDA guidelines, most drug firms are developing single enantiomers, spawning a \u201cchirotechnology\u201d industry","volume":"70","author":"Stinson","year":"1992","journal-title":"Chem. Eng. News"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1006\/bbrc.1994.1552","article-title":"Chiral discrimination of enantiomeric 2\u2032-deoxythymidine 5\u2032-triphosphate by HIV-1 reverse transcriptase and eukaryotic DNA polymerases","volume":"200","author":"Yamaguchi","year":"1994","journal-title":"Biochem. Biophys. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/nar\/23.15.2840","article-title":"Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing d- and l-thymidine 5\u2032-triphosphate as substrate","volume":"23","author":"Focher","year":"1995","journal-title":"Nucleic Acid Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/nar\/27.4.972","article-title":"Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: Role of the 3\u2032-hydroxyl group of the l-(\u03b2)-ribose in chiral discrimination between d- and l-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs","volume":"27","author":"Maga","year":"1999","journal-title":"Nucleic Acid Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/AAC.38.6.1292","article-title":"Anti-human immunodeficiency virus activities of the 1-L enantiomer of 2\u2032,3\u2032-dideoxycytidine and its 5-fluoro derivative in vitro in vitro","volume":"38","author":"Gosselin","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/AAC.37.6.1390","article-title":"The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2\u2032,3\u2032-dideoxyinosine and 2\u2032,3\u2032-dideoxycytidine confers high level resistance to the (\u2212) enantiomer of 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"37","author":"Gao","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1126\/science.1701568","article-title":"Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor","volume":"250","author":"Merluzzi","year":"1990","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Adams, J., and Merluzzi, V.J. (1993). The Search for Antiviral Drugs, Springer Verlag. Chapter 3.","DOI":"10.1007\/978-1-4899-6718-3"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/095632029901000601","article-title":"Non-nucleoside reverse transcriptase inhibitors: The NNRTI boom","volume":"10","author":"Pedersen","year":"1999","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/hiv.12044","article-title":"Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues","volume":"14","author":"Santoro","year":"2013","journal-title":"HIV Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2217\/fmb.11.7","article-title":"Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations","volume":"6","author":"Ibe","year":"2011","journal-title":"Future Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/jm00079a029","article-title":"Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor","volume":"35","author":"Mui","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1039\/C1OB06490H","article-title":"Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion","volume":"10","author":"Burke","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molstruc.2006.05.055","article-title":"Vibrational spectra and quantum mechanical calculations of antiretroviral drugs: Nevirapine","volume":"828","author":"Ayala","year":"2007","journal-title":"J. Mol. Struct."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1021\/ja0365781","article-title":"Enantioselective synthesis of \u201cquaternary\u201d 1,4-benzodiazepin-2-one scaffolds via memory of chirality","volume":"125","author":"Carlier","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.tet.2010.11.020","article-title":"Isolation of optically active nevirapine, a dipyridodiazepinone metabolite from the seeds of Cleome viscosa","volume":"67","author":"Chattopadhyay","year":"2011","journal-title":"Tetrahedron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ogunjale, A.O., and Okwundu, C.I. (2014). Rilpivirine versus efavirenz for initial therapy in treatment-naive, HIV-1-infected patients. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD010935"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1128\/AAC.39.12.2602","article-title":"L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase","volume":"39","author":"Young","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","unstructured":"Young, S.D., Britcher, S.F., Payne, L.S., Tran, L.O., and Lumma, W.C. (1996). Benzoxazinones as Inhibitors of HIV Reverse Transcriptase. (5,519,021), U.S. Patent."},{"key":"ref_56","unstructured":"Harms, A. (2007). The Art of Drug Synthesis, John Wiley and Sons. Chapter 6."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/ja9713791","article-title":"Lithium ephedrate-mediated addition of a lithium acetylide to a ketone: Solution structures and relative reactivities of mixed aggregates underlying the high enantioselectivities","volume":"120","author":"Thompson","year":"1998","journal-title":"J. Am. Chem. Soc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1021\/ja00086a066","article-title":"Highly Enantioselective alkynylation of aldehydes promoted by chiral oxazaborolidine","volume":"116","author":"Corey","year":"1994","journal-title":"J. Am. Chem. Soc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1021\/jo981170l","article-title":"Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor","volume":"63","author":"Pierce","year":"1998","journal-title":"J. Org. Chem."},{"key":"ref_60","unstructured":"Chen, C.Y., Tillyer, R.D., and Tan, L. (1998). Preparation of Chiral Tertiary Alcohols via Enantioselective Addition Reaction Using an Organozinc Reagent. (WO 98\/51676), Patent PCT."},{"key":"ref_61","first-page":"93","article-title":"Chiral separation of non-nucleoside reverse transcription inhibitor efavirenz by HPLC on cellulose-based chiral stationary phase","volume":"21","author":"Pujeri","year":"2013","journal-title":"J. Food Drug Anal."},{"key":"ref_62","first-page":"29","article-title":"Enantioseparation of efavirenz by ultra performance liquid chromatography","volume":"3","year":"2013","journal-title":"Adv. Anal. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.43.12.2893","article-title":"Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1","volume":"43","author":"Corbett","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/jm990580e","article-title":"Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors","volume":"43","author":"Corbett","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_65","unstructured":"Bacheler, L., Weislow, O., Snyder, S., Hanna, G., D\u2019Aquila, R., and The Sustiva Resistance Study Team (1998, January 1\u20135). Resistance to Efavirenz (Sustiva) in vivo. Proceedings of the Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.42.12.3123","article-title":"Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride","volume":"42","author":"Miller","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/S0040-4039(00)00331-2","article-title":"A new asymmetric 1,4-addition method: Application to the synthesis of the HIV non-nucleoside reverse transcriptase inhibitor DPC 961","volume":"41","author":"Magnus","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/jm00041a023","article-title":"Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"37","author":"Tucker","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/chir.1019","article-title":"Determination of the enantiomeric purity of investigational non-nucleoside reverse transcriptase inhibitors","volume":"13","author":"Aubry","year":"2001","journal-title":"Chirality"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0969-2126(01)00226-X","article-title":"The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design","volume":"3","author":"Renit","year":"1995","journal-title":"Structure"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1073\/pnas.90.5.1711","article-title":"Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of \u03b1-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase","volume":"90","author":"Pauwels","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/S0960-894X(01)00410-3","article-title":"Evolution of anti-HIV drug candidates. Part 1: From \u03b1-anilinophenylacetamide (\u03b1-APA) to imidoyl thiourea (ITU)","volume":"11","author":"Ludovici","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0960-894X(01)00411-5","article-title":"Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues","volume":"11","author":"Ludovici","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0960-894X(01)00412-7","article-title":"Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues","volume":"11","author":"Ludovici","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1025313705564","article-title":"On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data","volume":"17","author":"Lewis","year":"2003","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3851\/IMP1607","article-title":"Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors","volume":"20","author":"Coluccia","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cmdc.201000045","article-title":"Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"5","author":"Zeng","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cmdc.200800334","article-title":"Structural modifications of DAPY analogues with potent anti-HIV-1 activity","volume":"4","author":"Feng","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1016\/j.bmc.2011.07.023","article-title":"Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs","volume":"19","author":"Gu","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejmech.2012.04.004","article-title":"Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors","volume":"53","author":"Gu","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dof.2002.027.02.653978","article-title":"Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): The DABOs family","volume":"27","author":"Artico","year":"2002","journal-title":"Drugs Future"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1021\/jm101626c","article-title":"Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: New, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level","volume":"54","author":"Rotili","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1021\/jm201308v","article-title":"2-(Alkyl\/aryl)amino-6-benzylpyrimidin-4(3H)-ones as Inhibitors of wild-type and mutant HIV-1: Enantioselectivity studies","volume":"55","author":"Rotili","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1021\/jm00025a010","article-title":"Phenethylthiazolylthiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure\u2013activity relationship studies of PETT analogs","volume":"38","author":"Bell","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1021\/jm950639r","article-title":"Phenethylthiazolyl thiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure\u2013activity relationship studies of PETT analogs","volume":"39","author":"Cantrell","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.bcp.2004.01.019","article-title":"Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: Viral potency of chiral PETT derivatives","volume":"67","author":"Venkatachalam","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.bmc.2004.04.050","article-title":"Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds","volume":"12","author":"Venkatachalam","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/jm00061a022","article-title":"5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase","volume":"36","author":"Williams","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1021\/jm0211063","article-title":"Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: Synthesis and SAR studies","volume":"46","author":"Silvestri","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1021\/jm031147e","article-title":"Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations","volume":"47","author":"Silvestri","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/jm801470b","article-title":"Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and Coxsackie B4 virus","volume":"52","author":"Piscitelli","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2014.04.027","article-title":"New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"80","author":"Famiglini","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1021\/jm5011622","article-title":"Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"57","author":"Famiglini","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1073\/pnas.77.4.1736","article-title":"Analytical approximation to the accessible surface area of proteins","volume":"77","author":"Wodak","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/jm101142k","article-title":"Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"547","author":"Alexandre","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_96","first-page":"237","article-title":"IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection","volume":"11","author":"Klibano","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_97","unstructured":"Storer, R., Alexande, F.R., Dousson, C., Moussa, A.M., and Bridges, E. (2008). Enantiomerically Pure Phosphoindoles as HIV Inhibitors. (WO\/2008\/042240), Patent PCT."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0040-4039(02)02647-3","article-title":"Hewitt reaction revisited","volume":"44","author":"Afarinkia","year":"2003","journal-title":"Tetrahedron Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1039\/c3ob41667d","article-title":"Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts","volume":"11","author":"Han","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.tetasy.2012.08.015","article-title":"Enhanced efficiency of recyclable C3-symmetric cinchonine-squaramides in the asymmetric Friedel-Crafts reaction of indoles with alkyl trifluoropyruvate","volume":"23","author":"Han","year":"2012","journal-title":"Tetrahedron Asymmetry"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/2\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:19:13Z","timestamp":1760210353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/2\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,16]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["molecules21020221"],"URL":"https:\/\/doi.org\/10.3390\/molecules21020221","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,16]]}}}